Detection of high-grade cancers in the placebo group increased as the prostate size decreased. They found that prostate size in the fi nasteride group was 25 percent smaller than in the placebo group. Therefore, when the prostate size was taken into consideration, there was not a statistically signifi cant difference between the prevalence of high-grade prostate cancer in the two groups.
"If our conclusion that fi nasteride accelerates the detection of high-grade cancer yet may not promote its development is correct, then the implications regarding the clinical impact of this drug are quite favorable. The occurrence of lower grade tumors of questionable clinical signifi cance would be reduced, and the early detection of more serious tumors would be enhanced," the authors write.
In a second study, M. Scott Lucia, M.D., of the University of Colorado Health Sciences Center in Denver and colleagues investigated whether fi nasteride changes the appearance of tumor tissue so that lower-grade tumors are diagnosed as highgrade. The researchers examined surgically-removed prostates and high-grade prostate cancer biopsies from men treated with fi nasteride and a placebo for signs that fi nasteride affected prostate size, tumor size, or disease stage.
Like Cohen and colleagues, they found that men treated with fi nasteride had smaller prostate glands. High-grade tumors were not larger in men taking fi nasteride, but when they were present in surgically-removed prostates, the tumors were more likely to be detected because the prostates were usually smaller. They also found no major differences in tumor features between the two groups, indicating that it is unlikely that low-grade tumors were being classifi ed as high-grade.
"Although the evidence does not exclude the possibility that fi nasteride may have induced high-grade prostate cancer in some men, the analysis of prostatectomies from the PCPT does indicate that the relative increase in high-grade tumors in the fi nasteride group is less than originally believed. This evidence further suggests that increased detection … may have contributed to the fi nasteride-associated increase in high-grade disease," the authors write.
In an accompanying editorial, Gerald Andriole, M.D., of Washington University School of Medicine in St. Louis, Mo., and colleagues fi nd the evidence from these two studies important and convincing. "Taken together, the studies … provide substantial reassurance that the increased proportion of high-grade cancer on biopsy in PCPT is not likely to be clinically 
